RedHill Biopharma (RDHL) announced the U.S. government's Biomedical Advanced Research and Development Authority, or BARDA, has selected opaganib for development to treat exposure to Ebola virus disease. Under the cost-sharing contract, BARDA will provide partial funding for the company to further advance opaganib to mitigate infection and contain EBOV outbreaks.
Opaganib is currently in development for multiple oncology, viral, inflammatory and diabetes and obesity-related indications, including COVID-19, acute respiratory distress syndrome and radiological and chemical protection or mitigation.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com